Azione RPRX ROYALTY PHARMA PLC
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Royalty Pharma plc

Azioni

RPRX

GB00BMVP7Y09

Tempo differito Nasdaq
Altri mercati azionari
 19:00:00 03/07/2024 		Variaz. 5gg Var. 1 gen.
25,92 USD +0,15% Grafico intraday di Royalty Pharma plc -2,48% -7,73%
18/06 Royalty Pharma plc annuncia le dimissioni di Rory Balfour Riggs da direttore CI
17/06 Royalty Pharma plc annuncia le dimissioni di Mario Germano Giuliani da direttore CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Royalty Pharma plc(NasdaqGS:RPRX) added to Russell 1000 Defensive Index
Royalty Pharma plc(NasdaqGS:RPRX) added to Russell 1000 Value-Defensive Index
Royalty Pharma : Q2 2024 Pre-Quarterly Results Communication
Royalty Pharma : Goldman Sachs Healthcare Conference Transcript
Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director
Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Royalty Pharma Prices $1.5 Billion Debt Offering
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders.
Royalty Pharma : Vorasidenib Transaction Call Transcript
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
Royalty Pharma : Vorasidenib Transaction Press Release
Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
Royalty Pharma : BofA Health Care Conference Transcript
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione RPRX
  4. Notizie Royalty Pharma plc
  5. Altre lingue